Filing Flows › Neonc Technologies Holdings (NTHI) › Recalls, complaints & regulation

Neonc Technologies Holdings (NTHI): clinical trials

Neonc Technologies Holdings (NTHI) beyond its filings: 4 active clinical trials.

Neonc Technologies Holdings' latest quarter

Neonc Technologies Holdings, Q1 2025: revenue $40K (-7% year over year), net loss $38.0M, operating cash flow −$5.7M. The chart follows the revenue to costs, profit and cash.

Questions

How many clinical trials does Neonc Technologies Holdings have?

4 active studies on ClinicalTrials.gov, 0 in phase 3.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.